Cancer Genetics (NASDAQ: CGIX) and Chemed Corp. (NYSE:CHE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Cancer Genetics and Chemed Corp., as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cancer Genetics 0 1 2 0 2.67
Chemed Corp. 0 1 1 0 2.50

Cancer Genetics currently has a consensus price target of $6.00, indicating a potential upside of 118.18%. Chemed Corp. has a consensus price target of $214.50, indicating a potential upside of 6.08%. Given Cancer Genetics’ stronger consensus rating and higher possible upside, analysts clearly believe Cancer Genetics is more favorable than Chemed Corp..

Risk and Volatility

Cancer Genetics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Chemed Corp. has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Dividends

Chemed Corp. pays an annual dividend of $1.12 per share and has a dividend yield of 0.6%. Cancer Genetics does not pay a dividend. Chemed Corp. pays out 28.1% of its earnings in the form of a dividend. Chemed Corp. has increased its dividend for 8 consecutive years.

Profitability

This table compares Cancer Genetics and Chemed Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cancer Genetics -68.48% -48.78% -26.29%
Chemed Corp. 4.16% 26.18% 14.62%

Institutional & Insider Ownership

16.1% of Cancer Genetics shares are owned by institutional investors. Comparatively, 97.0% of Chemed Corp. shares are owned by institutional investors. 21.3% of Cancer Genetics shares are owned by company insiders. Comparatively, 5.3% of Chemed Corp. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Cancer Genetics and Chemed Corp.’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cancer Genetics $27.55 million 1.98 -$11.12 million ($1.05) -2.62
Chemed Corp. $1.62 billion 2.00 $226.52 million $3.99 50.68

Chemed Corp. has higher revenue and earnings than Cancer Genetics. Cancer Genetics is trading at a lower price-to-earnings ratio than Chemed Corp., indicating that it is currently the more affordable of the two stocks.

Summary

Chemed Corp. beats Cancer Genetics on 10 of the 16 factors compared between the two stocks.

About Cancer Genetics

Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. VITAS is the provider of hospice services in an industry dominated primarily by small, non-profit, community-based hospices. VITAS provides hospice care to Medicare beneficiaries participating in these managed care programs. A portion of its VITAS business is operated in the state of Florida. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers.

Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.